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there is a loss of integrity of brain cell membranes, such as in cases of head injury or brain hypoxia secondary to cardiac or respirato ry arrest. 6, 7 The following cases are illustrative of the presentations we have seen, and give insight into the contribution a detectable CK-BB activity can make to the management of these patients.
CASE 1
Case I was a 64-year-old man who was urgently referred to A&E by his GP with abdominal pain and swelling, and shortness of breath. He had been discharged from hospital 4 days previously after treatment for similar symptoms. Examination at the time of his previous episode revealed a tender and distended abdomen but a normal blood pressure and heart rate, and apyrexia. Past medical history was significant only for chronic obstructive airways disease, treated with salbutamol and beclomethasone. His biochemical investigations at that time showed normal electrolytes, urea, creatinine and amylase but mildly abnormal liver function tests [bilirubin 25 JlmoljL (reference range (RR) 2-17 JlmoljL), alkaline phosphatase 135 UjL (RR 35-125 UjL), alanine transaminase 166 U jL (RR < 35 U jL) and glutamyl transferase 391 UjL (RR < 50 UjL)]. Clinical symptoms at the time did not suggest the need for a CK request. Haematological investigations showed a raised white cell count (WCC) (15' I x 10 9 jL) with elevated neutrophils (11'6 x 10 9 jL) and a normal haemoglobin of 17·1 gjdL. On admission to a surgical ward a provisional diagnosis of cholangitis was made and the patient managed with IV fluids and antibiotics. Chest and abdominal X-rays revealed no signs of acute abdominal pathology, with no free gas seen on chest X-ray, and ultrasound scanning showed normal liver texture, with normal common bile duct, spleen and kidneys. The gall-bladder was contracted but the pancreas and aorta were obscured.' The patient's condition settled and he was discharged after 9 days, comfortable and pain-free.
Blood samples taken on the second admission indicated a worsening of liver function, with a bilirubin of 170Ilmol/L and glutamyl transferase of 1570 U/L. Because of the shortness of breath total CK was analysed to exclude myocardial infarction (MI). The total activity was 229 U/L (RR 33-197 U/L) but electrophoresis revealed a CK-BB concentration of 86 U/L. A second sample the following day confirmed these findings, with a total CK of 250 U/L and CK-BB of 138 U/L. The possibility of a neuroendocrine tumour was conveyed to the ward. Over the next 10 days the patient's clinical condition deteriorated, with increasing jaundice, ascitic fluid formation and abdominal distension. A further CK 5 days post-admission was 420 U/L, with CK-BB of 146 U/L. Ultrasound scan of the liver now showed marked enlargement but with no focal lesion. However, ultrasound heterogeneity suggested widespread metastatic involvement. The mucin marker CA 19-9 (elevated in 80% of patients with advanced pancreatic carcinoma) was 2090 kU/L (RR 0-35 kU/L). Continued worsening of the patient's condition suggested disseminated malignancy as the probable diagnosis, and the patient died 12 days after the second admission. Post mortem examination revealed small cell carcinoma of the lung, with metastases in lymph nodes, liver and bone. The brain showed no abnormality.
CASE 2
Case 2 was a 67-year-old woman who was admitted to hospital with increasing fatigue and muscle weakness, together with ankle swelling and dyspnoea. She was a known hypertensive and had chronic obstructive airways disease in the past. Current medication was frusemide and potassium. Blood was taken on admission for urea and electrolyte analysis, which revealed profound hypokalaemia, the potassium being 1-4mmol/L, This was thought to be diureticinduced as the patient had not had diarrhoea or been vomiting. Because of the shortness of breath, CK estimation was requested, which showed a total CK activity of 79 U/L, a CK-BB of 6 U/L, but with no CK-MB. This was confirmed by further samples over the next 2 days, in which total CK activities of 80 and 76 U/L and CK-BB activities of 16 U/L and 7 U/L, respectively, were measured. The possibility of a neuro-endocrine tumour was conveyed to the ward, and further investigations were directed towards this. A CT scan of the lungs and a bronchial biopsy were ordered, the CT scan being reported as showing likely carcinoma of the bronchus with mediastinal metastases. A later bronchial biopsy report indicated the bronchial mucosa to be infiltrated by small cell carcinoma. The patient's condition deteriorated and she died 29 days post-admission. The final diagnosis was small cell carcinoma of the lung.
CASE 3
Case 3 is a 74-year-old man who presented to A&E with sudden onset of shortness of breath but no palpitations, nausea or current chest pain, although he had recently been troubled by chest pain. On examination he was comfortable, not cyanosed and had a blood pressure of 150/ 90 mmHg. ECG examination revealed atrial fibrillation and evidence of an old inferior MI, but no current acute changes. Biochemical and haematological tests on admission were generally unremarkable except for a total CK of 370 U/L, which on electrophoresis revealed a CK-BB macroform, making accurate quantitation ofCK-BB unreliable. The elevated total CK and the CK-BB macroform were confirmed the following day. Because of the identification of the CK-BB macroform blood samples were sent for analysis for other tumour markers, and revealed moderately raised levels of prostatespecific antigen (PSA) and CA-125 (see Table 1 ). The patient was discharged, with follow-up on an out-patient basis. Two months later the patient presented again to A&E with shortness of breath and chest pain, a total CK at this time being 290 U/L, again with a CK-BB macroform.
During the course of the next 12 months the patient continued to present with episodes of anginal chest pain and fast atrial fibrillation (AF). One such episode was diagnosed as a further MI, biochemical analysis showing a cardiac troponin T level of 0·31 Ilg/mL (RR<0'2Ilg/mL) and CK-MB mass of 49 Ilg/ mL (RR < 6 Ilg/mL). Total CK at that time was 608 U/L, again with macroform CK-BB. On this occasion a blood sample was sent for analysis of y, y-enolase ('neuron specific' enolase), the concentration of which was elevated at 37 Ilg/ mL (RR<12·5Ilg/mL). The levels of other tumour markers are shown in Table 1 ; attempts to locate the source of these have so far been negative, although prostatic hypertrophy persists. A CT scan of the liver and lungs showed no abnormality, and ultrasound examination detected no abnormality of the pancreas, spleen and kidneys. A bone scan revealed no obvious skeletal deposits. The patient continues to present at regular intervals.
RETROSPECTIVE STUDY
In a retrospective study, designed to assess the incidence and value of CK-BB detection in the investigation of chest pain, we reviewed all the requests made for CK as a chest pain marker over a 6-month period from January 1997. During that time we analysed 16062 samples for total CK, of which 5665 (35'5%) were further analysed by CK electrophoresis. From this selection, 124 samples (2'2%) from 116 patients had a CK-BB activity of greater than 3 U/L, with a range of CK-BB of 3-72 U/L. We were able to review the clinical notes in 55 of these patients, and the findings relating to the raised CK-BB are presented in Table 2 . Of these 55 cases cerebral causes were thought to account for the raised CK-BB in 17 (31%), confirmed or suspected malignancy (defined as an increase in other tumour markers or strong clinical signs) in 12 (22%) and in 26 cases we were unable to determine any cause, usually because the patient was discharged from A&E and lost to follow-up. The patients with confirmed or suspected malignancy had a significantly higher mean CK-BB (28,2 U/L) than those with an increase due to a cerebral cause (13·2U/L) (P=0'04, t-test). Those patients with a CK-BB of undetermined cause had the lowest mean of any group.
DISCUSSION
This study has shown that over a 6-month sampling period, a significant number of patients presenting with chest pain had a CK-BB of greater than 3 U/L. This number would equate to over 200 patients per annum attending our A&E (140000 patient attendances per year). Whilst not adding immediately to patient management, which would focus initially on acute cardiac pathology, the presence of a significant CK-BB, particularly when confirmed, should direct further investigational effort appropriately. Diagnostic differentiation should be between a cerebral event (e.g., head injury, or hypoxia due to cardiac or respiratory arrest or stroke) or tumour secretion, although conceivably the two may coexist. Increases in CK-BB due to cerebral causes tend to be transient, as the elimination half-life of CK-BB is between 5 and 16 h 6 and the hypoxia is reversible, thus samples taken on subsequent days may well be negative for CK-BB. The extent of the elevation of the CK-BB may act as a guide to the source, as higher values have been associated with malignancy," which was confirmed with the finding of a significantly higher mean CK-BB in our series. Cases 1 and 2 illustrate situations in which persistent elevation of CK-BB, even at low total CK activities, was suggestive of secretion by a neuro-endocrine tumour, which was subsequently confirmed. Whilst probably not influencing outcome, earlier identification of the clinical condition may have eased management of these patients. Case 3 is illustrative of the problems associated with a macroform CK-BB, typically a complex of CK-BB and an immunoglobulin, usually IgG, sometimes known as 'macro creatine kinase, type 1'.s This patient exhibited a persistently raised total CK for over 15 months due to the presence of a macroform molecule, associated at various times with moderately increased levels of other tumour antigens (PSA, y, y-enolase and CA 125). Despite elevation of these markers malignancy has not been proven, consistent with other reported occurrences of this macromolecule.v!? As the prevalence of macro form CK-BB has been estimated to be between I % and 6% in hospital populations.v'? presentations of this type may occasionally cause diagnostic problems. The significance of the elevation of the other tumour markers in Case 3 is therefore unclear; they may represent secretion by an as yet unidentified tumour or may simply reflect abnormal protein binding, as in the case of CK-BB.
This study has shown that a significant number of patients presenting to A&E with chest pain may have a detectable CK-BB Creatine kinase-BB in chest pain 529 concentration, even with total CK activity within the reference range. This has in a number of cases (including those presented here) allowed the laboratory to alert the clinician to a noncardiac, possibly malignant cause of the symptoms, and to suggest further appropriate investigations. In the case of cerebral causes the increase in CK-BB may account for the increase in total CK, particularly if CK-MB is normal.
With the introduction of more specific cardiac markers, particularly the cardiac troponins, the ability to differentiate cardiac from non-cardiac events may be improved, but information available from the electrophoretic CK isoenzyme profile will be lost. For a significant number of our chest pain presentations this may mean the loss of an earlier diagnostic opportunity.
